| 1 |
34329582 | The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. | 2022 Feb 17 |
1 |
| 2 |
33536335 | SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors. | 2021 Feb 9 |
1 |
| 3 |
27440269 | PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. | 2017 Jan 15 |
1 |
| 4 |
27708213 | Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. | 2016 Nov 22 |
3 |